Is There a Role for Dual PI3K/mTOR Inhibitors for Patients Affected with Lymphoma?

par Tarantelli, Chiara, Lupia, Antonio, Stathis, Anastasios, Bertoni, Francesco
Publié dans Int J Mol Sci (2020)

An Unusual Case of Plasmablastic Lymphoma Presenting as Paravertebral Mass Evaluated by (18) F-FDG PET/CT

par Treglia, Giorgio, Paone, Gaetano, Stathis, Anastasios, Ceriani, Luca, Giovanella, Luca
Publié 2013

Genetic alterations in systemic nodal and extranodal non‐cutaneous lymphomas derived from mature T cells and natural killer cells

par Boi, Michela, Stathis, Anastasios, Zucca, Emanuele, Inghirami, Giorgio, Bertoni, Francesco
Publié dans Cancer Sci (2012)

Adverse Event Reporting with Immune Checkpoint Inhibitors in Older Patients: Age Subgroup Disproportionality Analysis in VigiBase

par Noseda, Roberta, Bonaldo, Giulia, Motola, Domenico, Stathis, Anastasios, Ceschi, Alessandro
Publié dans Cancers (Basel) (2021)

Do oncologists prefer subspecialty radiology reports? A quality care study

par Rizzo, Stefania, Del Grande, Maria, Espeli, Vittoria, Stathis, Anastasios, Nicolino, Gabriele Maria, Del Grande, Filippo
Publié dans Insights Imaging (2021)

Safety, tolerability, and preliminary activity of IMGN529, a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a dose-esca...

par Stathis, Anastasios, Flinn, Ian W., Madan, Sumit, Maddocks, Kami, Freedman, Arnold, Weitman, Steven, Zucca, Emanuele, Munteanu, Mihaela C., Lia Palomba, M.
Publié dans Invest New Drugs (2018)

Novel HDAC inhibitors exhibit pre-clinical efficacy in lymphoma models and point to the importance of CDKN1A expression levels in mediating their anti-tumor response

par Mensah, Afua Adjeiwaa, Kwee, Ivo, Gaudio, Eugenio, Rinaldi, Andrea, Ponzoni, Maurilio, Cascione, Luciano, Fossati, Gianluca, Stathis, Anastasios, Zucca, Emanuele, Caprini, Gianluca, Bertoni, Francesco
Publié dans Oncotarget (2014)

The Bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) demonstrated synergies with other anti-lymphoma targeted agents

par Tarantelli, Chiara, Zhang, Lu, Curti, Elisabetta, Gaudio, Eugenio, Spriano, Filippo, Priebe, Valdemar, Cascione, Luciano, Arribas, Alberto J., Zucca, Emanuele, Rossi, Davide, Stathis, Anastasios, Bertoni, Francesco
Publié dans Haematologica (2019)

Bromodomain inhibitor OTX015 (MK-8628) combined with targeted agents shows strong in vivo antitumor activity in lymphoma

par Gaudio, Eugenio, Tarantelli, Chiara, Ponzoni, Maurilio, Odore, Elodie, Rezai, Keyvan, Bernasconi, Elena, Cascione, Luciano, Rinaldi, Andrea, Stathis, Anastasios, Riveiro, Eugenia, Cvitkovic, Esteban, Zucca, Emanuele, Bertoni, Francesco
Publié dans Oncotarget (2016)

Clinical Response of Carcinomas Harboring the BRD4-NUT Oncoprotein to the Targeted Bromodomain Inhibitor OTX015/MK-8628

par Stathis, Anastasios, Zucca, Emanuele, Bekradda, Mohamed, Gomez-Roca, Carlos, Delord, Jean-Pierre, de La Motte Rouge, Thibault, Uro-Coste, Emmanuelle, de Braud, Filippo, Pelosi, Giuseppe, French, Christopher A.
Publié dans Cancer Discov (2016)

The Novel TORC1/2 Kinase Inhibitor PQR620 Has Anti-Tumor Activity in Lymphomas as a Single Agent and in Combination with Venetoclax

par Tarantelli, Chiara, Gaudio, Eugenio, Hillmann, Petra, Spriano, Filippo, Sartori, Giulio, Aresu, Luca, Cascione, Luciano, Rageot, Denise, Kwee, Ivo, Beaufils, Florent, Zucca, Emanuele, Stathis, Anastasios, Wymann, Matthias P., Cmiljanovic, Vladimir, Fabbro, Doriano, Bertoni, Francesco
Publié dans Cancers (Basel) (2019)

A Phase 1 study of BAL101553, a novel tumor checkpoint controller targeting microtubules, administered as 48-h infusion in adult patients with advanced solid tumors

par Joerger, Markus, Stathis, Anastasios, Metaxas, Yannis, Hess, Dagmar, Mantiero, Mara, Mark, Michael, Volden, Matthias, Kaindl, Thomas, Engelhardt, Marc, Larger, Patrice, Lane, Heidi, Hafner, Peter, Levy, Nicole, Stuedeli, Silvia, Sessa, Cristiana, von Moos, Roger
Publié dans Invest New Drugs (2019)

Study of the antilymphoma activity of pracinostat reveals different sensitivities of DLBCL cells to HDAC inhibitors

par Mensah, Afua Adjeiwaa, Spriano, Filippo, Sartori, Giulio, Priebe, Valdemar, Cascione, Luciano, Gaudio, Eugenio, Tarantelli, Chiara, Civanelli, Elisa, Aresu, Luca, Rinaldi, Andrea, Damia, Giovanna, Lovati, Emanuela, Zucca, Emanuele, Stathis, Anastasios, Pietra, Claudio, Bertoni, Francesco
Publié dans Blood Adv (2021)

Pembrolizumab in relapsed or refractory Richter syndrome

par Armand, Philippe, Murawski, Niels, Molin, Daniel, Zain, Jasmine, Eichhorst, Barbara, Gulbas, Zafer, Hawkes, Eliza A., Pagel, John M., Phillips, Tycel, Ribrag, Vincent, Svoboda, Jakub, Stathis, Anastasios, Chatterjee, Arkendu, Orlowski, Robert, Marinello, Patricia, Christian, Beth
Publié dans Br J Haematol (2020)

SAKK38/07 study: integration of baseline metabolic heterogeneity and metabolic tumor volume in DLBCL prognostic model

par Ceriani, Luca, Gritti, Giuseppe, Cascione, Luciano, Pirosa, Maria Cristina, Polino, Angela, Ruberto, Teresa, Stathis, Anastasios, Bruno, Andrea, Moccia, Alden A., Giovanella, Luca, Hayoz, Stefanie, Schär, Sämi, Dirnhofer, Stefan, Rambaldi, Alessandro, Martinelli, Giovanni, Mamot, Christoph, Zucca, Emanuele
Publié dans Blood Adv (2020)

Bromodomain and extra-terminal domain inhibition modulates the expression of pathologically relevant microRNAs in diffuse large B-cell lymphoma

par Mensah, Afua A., Cascione, Luciano, Gaudio, Eugenio, Tarantelli, Chiara, Bomben, Riccardo, Bernasconi, Elena, Zito, Domenico, Lampis, Andrea, Hahne, Jens C., Rinaldi, Andrea, Stathis, Anastasios, Zucca, Emanuele, Kwee, Ivo, Gattei, Valter, Valeri, Nicola, Riveiro, Maria E, Bertoni, Francesco
Publié dans Haematologica (2018)

BET bromodomain inhibitor birabresib in mantle cell lymphoma: in vivo activity and identification of novel combinations to overcome adaptive resistance

par Tarantelli, Chiara, Bernasconi, Elena, Gaudio, Eugenio, Cascione, Luciano, Restelli, Valentina, Arribas, Alberto Jesus, Spriano, Filippo, Rinaldi, Andrea, Mensah, Afua Adjeiwaa, Kwee, Ivo, Ponzoni, Maurilio, Zucca, Emanuele, Carrassa, Laura, Riveiro, Maria E, Rezai, Keyvan, Stathis, Anastasios, Cvitkovic, Esteban, Bertoni, Francesco
Publié dans ESMO Open (2018)

Antitumor activity of the dual BET and CBP/EP300 inhibitor NEO2734

par Spriano, Filippo, Gaudio, Eugenio, Cascione, Luciano, Tarantelli, Chiara, Melle, Federica, Motta, Giovanna, Priebe, Valdemar, Rinaldi, Andrea, Golino, Gaetanina, Mensah, Afua Adjeiwaa, Aresu, Luca, Zucca, Emanuele, Pileri, Stefano, Witcher, Michael, Brown, Bill, Wahlestedt, Claes, Giles, Francis, Stathis, Anastasios, Bertoni, Francesco
Publié dans Blood Adv (2020)

The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity compared to SAR3419 in CD19-positive lymphoma and leukemia models

par Hicks, Stuart W., Tarantelli, Chiara, Wilhem, Alan, Gaudio, Eugenio, Li, Min, Arribas, Alberto J., Spriano, Filippo, Bordone, Roberta, Cascione, Luciano, Lai, Katharine C., Qiu, Qifeng, Taborelli, Monica, Rossi, Davide, Stussi, Georg, Zucca, Emanuele, Stathis, Anastasios, Sloss, Callum M., Bertoni, Francesco
Publié dans Haematologica (2019)

Phase I study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomas

par Stathis, Anastasios, Hotte, Sebastien J., Chen, Eric X., Hirte, Holger W., Oza, Amit M., Moretto, Patricia, Webster, Sheila, Laughlin, Anne, Stayner, Lee-Anne, McGill, Shauna, Wang, Lisa, Zhang, Wen-jiang, Espinoza-Delgado, Igor, Holleran, Julianne L., Egorin, Merrill J., Siu, Lillian L.
Publié 2009